As Neptune Tech & Bioressources (NEPT) Market Valuation Rose, Holder Wynnefield Capital Has Trimmed Its Stake by $380,000; Amgen (AMGN) Holder First Citizens Bank & Trust Co Has Decreased Its Position

August 10, 2018 - By Sarah Holford

Amgen Inc. (NASDAQ:AMGN) Logo

Wynnefield Capital Inc decreased its stake in Neptune Tech & Bioressources (NEPT) by 19% based on its latest 2018Q1 regulatory filing with the SEC. Wynnefield Capital Inc sold 190,000 shares as the company’s stock rose 3.96% while stock markets declined. The hedge fund held 810,000 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $2.28M, down from 1.00M at the end of the previous reported quarter. Wynnefield Capital Inc who had been investing in Neptune Tech & Bioressources for a number of months, seems to be less bullish one the $217.73M market cap company. The stock decreased 1.08% or $0.03 during the last trading session, reaching $2.75. About 117,426 shares traded. Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT) has risen 160.36% since August 10, 2017 and is uptrending. It has outperformed by 147.79% the S&P500. Some Historical NEPT News: 18/05/2018 – G NEPTUNE BHD GNET.KL – APPOINTS HAJI MOHD AMRAN BIN WAHID AS NON EXECUTIVE CHAIRMAN; 26/03/2018 – VEIDEKKE ASA VEI.OL – NESBUKTA 6 AS, OWNED 50/50 BY BÅTGUTTA AS AND NEPTUNE PROPERTIES AS, HAS SIGNED A CONTRACT WITH VEIDEKKE; 30/05/2018 – AWS REPORTS GENERAL AVAILABILITY OF AMAZON NEPTUNE; 20/05/2018 – WorleyParsons Says Wins Neptune Energy Contact for Nova Field Tie-back; 26/04/2018 – McConnell AF Bse: McConnell participates in Neptune Falcon; 04/04/2018 – Federal Register: Petition for Exemption; Summary of Petition Received; Neptune Aviation Transport Services, Inc; 14/03/2018 – Infra investor sells Neptune transmission stake; 19/04/2018 – FBO:Veteran Aff: Veterans Affairs Contract Award – J–Neptune 2 Rover & Docker Service 664C80237 – 36C26218Q0503; 03/05/2018 – Neptune Technologies Short-Interest Ratio Rises 25% to 10 Days; 14/05/2018 – NEPTUNE MARINE SERVICES LTD NMS.AX – FY REVENUE FROM ORDINARY ACTIVITIES DOWN 17.34 PCT TO $67.7 MLN

First Citizens Bank & Trust Co decreased its stake in Amgen Inc (AMGN) by 57.89% based on its latest 2018Q1 regulatory filing with the SEC. First Citizens Bank & Trust Co sold 14,789 shares as the company’s stock declined 5.44% with the market. The hedge fund held 10,756 shares of the biological products (no diagnostic substances) company at the end of 2018Q1, valued at $1.83 million, down from 25,545 at the end of the previous reported quarter. First Citizens Bank & Trust Co who had been investing in Amgen Inc for a number of months, seems to be less bullish one the $125.69 billion market cap company. The stock increased 0.11% or $0.21 during the last trading session, reaching $194.18. About 1.16 million shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 14.68% since August 10, 2017 and is uptrending. It has outperformed by 2.11% the S&P500. Some Historical AMGN News: 10/03/2018 – REGENERON, SANOFI CHOLESTEROL DRUG PRALUENT SUCCEEDS IN MAJOR “OUTCOMES” STUDY – DATA; 18/05/2018 – Moody’s: Aimovig Approval Credit Positive For Amgen And Novartis; 23/03/2018 – AMGEN CONFIRMS POSITIVE CHMP OPINION RECOGNIZING REPATHA; 25/04/2018 – Amgen posts higher first quarter profit as sales rise 3 percent; 17/05/2018 – FDA OKS AIMOVIG FOR PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS; 21/05/2018 – AMGEN INC – SAFETY RESULTS WERE CONSISTENT WITH KNOWN SAFETY PROFILE OF PROLIA; 17/05/2018 – ICYMI very interesting paper that anti-CGRP may be used to treat highly invasive bacterial infections; 23/03/2018 – Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes; 10/03/2018 – REGENERON, SANOFI STUDY OF PRALUENT PRESENTED AT ACC; 16/05/2018 – Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Establ

Another recent and important Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT) news was published by Gurufocus.com which published an article titled: “Neptune to Hold Conference Call to Discuss First Quarter Results for the Three Months Period Ended June 30, 2018” on July 31, 2018.

Wynnefield Capital Inc, which manages about $319.90M and $287.44M US Long portfolio, upped its stake in New York & Co (NYSE:NWY) by 465,000 shares to 724,805 shares, valued at $2.45 million in 2018Q1, according to the filing.

Investors sentiment decreased to 1.08 in 2018 Q1. Its down 0.59, from 1.67 in 2017Q4. It turned negative, as 5 investors sold NEPT shares while 8 reduced holdings. 6 funds opened positions while 8 raised stakes. 11.28 million shares or 4.88% more from 10.75 million shares in 2017Q4 were reported. 340 were accumulated by Howe And Rusling. 2,223 were reported by Bankshares Of Montreal Can. Citadel Advsrs Ltd Liability Company reported 38,070 shares. Royal Natl Bank Of Canada reported 0% in Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT). Northwest Inv Counselors Lc has 0.07% invested in Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT) for 57,369 shares. Morgan Stanley reported 31,455 shares. Credit Agricole S A reported 15 shares stake. Invesco Ltd reported 16,347 shares or 0% of all its holdings. 9,408 are owned by Comml Bank Of America De. Millennium Ltd Liability Corporation invested in 13,600 shares or 0% of the stock. Wells Fargo Communications Mn accumulated 11 shares or 0% of the stock. Grp One Trading Lp has invested 0% in Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT). Alpine Management Limited Com reported 184,993 shares stake. Blair William And Com Il owns 20,800 shares. Stratos Wealth Prtnrs Limited accumulated 38 shares.

First Citizens Bank & Trust Co, which manages about $735.61 million US Long portfolio, upped its stake in Sei Investments Co (NASDAQ:SEIC) by 6,260 shares to 15,618 shares, valued at $1.17 million in 2018Q1, according to the filing. It also increased its holding in Spdr S&P Midcap 400 Etf Tr (MDY) by 4,478 shares in the quarter, for a total of 18,960 shares, and has risen its stake in Cognizant Technology Solutio (NASDAQ:CTSH).

Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on October, 24. They expect $3.38 EPS, up 3.36% or $0.11 from last year’s $3.27 per share. AMGN’s profit will be $2.19 billion for 14.36 P/E if the $3.38 EPS becomes a reality. After $3.83 actual EPS reported by Amgen Inc. for the previous quarter, Wall Street now forecasts -11.75% negative EPS growth.

Among 26 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 15 Hold. Therefore 42% are positive. Amgen Inc. had 95 analyst reports since August 3, 2015 according to SRatingsIntel. The firm earned “Equal-Weight” rating on Thursday, April 5 by Barclays Capital. Jefferies maintained the shares of AMGN in report on Friday, July 27 with “Buy” rating. On Monday, September 7 the stock rating was upgraded by UBS to “Buy”. The rating was maintained by Morgan Stanley with “Overweight” on Friday, October 6. Argus Research upgraded Amgen Inc. (NASDAQ:AMGN) rating on Tuesday, January 23. Argus Research has “Buy” rating and $220 target. The company was maintained on Friday, February 2 by BMO Capital Markets. The firm earned “Buy” rating on Sunday, October 29 by Mizuho. The company was downgraded on Wednesday, April 5 by Jefferies. Credit Suisse maintained it with “Outperform” rating and $186 target in Friday, September 29 report. The firm has “Buy” rating given on Wednesday, February 1 by Bank of America.

More important recent Amgen Inc. (NASDAQ:AMGN) news were published by: Benzinga.com which released: “Nasdaq, Tech Names Might Come Under Pressure Following Facebook’s Weak Results” on July 26, 2018, also 247Wallst.com published article titled: “Why Have Short Sellers Backed Off Major Biotechs?”, Seekingalpha.com published: “BeiGene launches late-stage study of tislelizumab in first-line lung cancer” on August 09, 2018. More interesting news about Amgen Inc. (NASDAQ:AMGN) was released by: Fool.com and their article: “Better Buy: Gilead Sciences, Inc. vs. Amgen Inc.” with publication date: August 08, 2018.

Investors sentiment decreased to 0.88 in 2018 Q1. Its down 0.34, from 1.22 in 2017Q4. It fall, as 67 investors sold AMGN shares while 557 reduced holdings. 114 funds opened positions while 435 raised stakes. 502.72 million shares or 8.88% less from 551.71 million shares in 2017Q4 were reported. Cibc has invested 0.05% in Amgen Inc. (NASDAQ:AMGN). Hartford Investment owns 133,750 shares or 0.45% of their US portfolio. Segall Bryant And Hamill Ltd holds 0.04% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 8,889 shares. Checchi Capital Advisers Lc, California-based fund reported 6,318 shares. Estabrook Capital Management holds 0% or 40,342 shares. Highland Mgmt Ltd Liability owns 27,195 shares. Envestnet Asset Mngmt stated it has 0.03% in Amgen Inc. (NASDAQ:AMGN). Jefferies Gp Lc owns 75,727 shares or 0.07% of their US portfolio. 7,636 were accumulated by Intrust State Bank Na. Cibc Ww Markets invested in 0.3% or 163,910 shares. Wealth Architects Llc owns 1,981 shares or 0.11% of their US portfolio. State Farm Mutual Automobile Insur Company has 3.26 million shares. Regent Invest Mgmt Ltd Limited Liability Company invested 0.16% in Amgen Inc. (NASDAQ:AMGN). Narwhal Capital has 0.31% invested in Amgen Inc. (NASDAQ:AMGN). Raymond James & Assocs, a Florida-based fund reported 705,908 shares.

Amgen Inc. (NASDAQ:AMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts